Renalytix to Present at 40th Annual J.P. Morgan Virtual Healthcare Conference
Renalytix plc (NASDAQ: RNLX) announces its participation in the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) announces its participation in the 40th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 12, 2022, at 2:15 p.m. EST. Interested investors can access the live and archived webcast on the company’s investors page. Renalytix is pioneering bioprognosis for kidney health, with its flagship product, KidneyIntelX, receiving FDA Breakthrough Designation aimed at improving kidney disease management and patient care. For more details, visit www.renalytix.com.
Details
News Market Reaction – RNLX
The recorded move for RNLX in the trading session of this news was -1.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference.
Renalytix’s management is scheduled to present on Wednesday, January 12, 2022, at 2:15 p.m. EST. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at investors.renalytix.com.
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
For further information, please contact:
| Renalytix plc | www.renalytix.com | ||
| James McCullough, CEO | Via Walbrook PR | ||
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | ||
| Alex Price / Nicholas Moore | |||
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | ||
| Gary Clarence / Daniel Adams | |||
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | ||
| Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
| CapComm Partners | |||
| Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com | ||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.